Published in Cell Stem Cell · View the paper (DOI)
Researchers have created a new investigational drug that traps IGFBP3, preventing gastrointestinal symptoms and restoring the intestine's mucosal lining structure. The drug may hold promise as a potential treatment for diabetic enteropathy, a common complication of type 1 diabetes.
Coverage from 2 institutions